Categories:

• Agriculture and Forestry
• Automotive
• Biotechnology and Pharmaceuticals
• Chemicals
• Construction and Maintenance
• Consumer Goods and Services
• Electronics and Electrical
• Energy and Environment
• Food and Related Products
• Industrial Goods and Services
• Information Technology
• Materials
• Real Estate
• Telecommunications
• Textiles and Nonwovens
• Transportation and Logistics

Popular Tags:

• player
• mp4
• mp4 player
• screen
• player screen
• screen mp4
• 4gb
• player 4gb
• 4gb mp4
• card
• slot
• player card
• 18inch
• inch
• 15inch
• inch mp4
• inch player
• flash
• style
• builtin

Home › advanced

 

Tag: advanced

Central Hudson Gas & Electric to Deploy Advanced Distribution Management System

2016-06-09 00:38:00| Transmission & Distribution World

Schneider Electric and Central Hudson Gas & Electric Corp. have plans to deploy Schneider Electric's Advanced Distribution Management System (ADMS). read more

Tags: system advanced management central

New Data for KEYTRUDA (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting

2016-06-05 14:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three separate studies evaluating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in combination with other treatment regimens including talimogene laherparepvec, dabrafenib plus trametinib, or low-dose ipilimumab in patients with advanced melanoma. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestor Contacts:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data advanced presented meeting

New KEYTRUDA (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meeting

2016-06-04 14:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. New Analysis from KEYNOTE-010, Comparing KEYTRUDA to Chemotherapy, Shows Improved Survival Benefit in Patients with Increased Levels of PD-L1 Expression KEYNOTE-001 Findings Show Responses Are Durable and Include Two Year Overall Survival Data for KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data, including updated response rates, progression-free survival (PFS) and overall survival (OS) with KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy in patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1 from two studies: KEYNOTE-010 and KEYNOTE-001. Language: English Contact: MerckMedia Contacts:Pamela Eisele, (267) 305-3558orCourtney Ronaldo, (908) 236-1108orInvestor Contacts:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: including data advanced presented

Secant Group's New Business Framework Brings Innovative Products To Market Through Advanced Materials And Process Technologies

2016-06-03 08:03:28| textileweb Home Page

Defining the future of advanced materials and engineered products is the ambitious vision set by the newly named US corporation, the Secant Group, LLC

Tags: business advanced products process

Illinois Alderman Wants to Hold Neighborhood Meeting over Settlement with Advanced Disposal

2016-06-02 11:39:00| Waste Age

City officials and an environmental group of citizens are trying to figure out what to do about the settlement. read more

Tags: with advanced hold meeting

Sites : [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] next »